ReviewNature reviews. Urology2016
An update on focal therapy for prostate cancer.
Review in Nature reviews. Urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Pathologic failure and salvage approaches following focal therapy for localized prostate cancer.The Canadian journal of urology · 2026Article
- AI-assisted cryo-dose estimation and tissue injury modeling for assessing side effects in MRI-guided prostate cryoablation: a retrospective study.Physics in medicine and biology · 2026Article
- Evolution of Active Surveillance of Prostate Cancer: Impact of Magnetic Resonance Imaging, Magnetic Resonance Imaging-Guided Biopsy, and Focal Therapy.The Journal of urology · 2025Article
- Post-Treatment Imaging in Focal Therapy: Understanding TARGET and PI-FAB Scoring Systems.Diagnostics (Basel, Switzerland) · 2025Review
- A mitochondrion-targeted cyanine agent for NIR-II fluorescence-guided surgery combined with intraoperative photothermal therapy to reduce prostate cancer recurrence.Journal of nanobiotechnology · 2024Article
- Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study.Scientific reports · 2024Article
- Development and therapeutic evaluation of 5D3(CC-MLN8237)Frontiers in pharmacology · 2024Article
- Real-Time and Delayed Imaging of Tissue and Effects of Prostate Tissue Ablation.Current urology reports · 2023Review
- Rectourethral fistula following focal irreversible electroporation for prostate cancer.BMJ case reports · 2022Article
- Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial.JAMA surgery · 2022Article
- Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes.BMC urology · 2022Article
- Preclinical evaluation of a clinical prototype transrectal diffuse optical tomography system for monitoring photothermal therapy of focal prostate cancer.Journal of biomedical optics · 2022Article
- A multi-object deep neural network architecture to detect prostate anatomy in T2-weighted MRI: Performance evaluation.Frontiers in nuclear medicine · 2022Article
- Sentinel Lymph Node Biopsy in Prostate Cancer Patients: Results From an Injection Technique Targeting the Index Lesion in the Prostate Gland.Frontiers in medicine · 2022Article
- Urethra-sparing surgery for a prostate cancer lesion in the anterior urethral zone with magnetic resonance-guided focused ultrasound: a case report.Translational cancer research · 2021Article
- Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution.Translational andrology and urology · 2021Article
- Focal therapy for primary and salvage prostate cancer treatment: a narrative review.Translational andrology and urology · 2021Review
- Perceptions of partial gland ablation for prostate cancer among men on active surveillance: A qualitative study.BMJ surgery, interventions, & health technologies · 2021Article
- Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).World journal of urology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, the increased uptake of serum PSA level screening led to an increase in the number of diagnoses of low-risk and intermediate-risk prostate cancer. Traditionally, these patients have been considered for either active surveillance programmes or radical whole-gland therapies, such as prostatectomy or radiotherapy. Focal therapy is an emerging treatment option that involves the focal ablation of prostate cancer with preservation of surrounding healthy tissue. This approach might result in reduced morbidity when compared with whole-gland therapies. In current practice, much controversy surrounds optimal patient selection and preoperative tumour localization strategies. Focal therapy modalities include cryotherapy, high-intensity focused ultrasound, laser ablation, photodynamic therapy, irreversible electroporation, radiofrequency ablation and focal brachytherapy. However, as long-term oncological data for focal therapies are lacking, formal recommendations for its use cannot be made.
Indexed as
Identifiers
27670618What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.